About ERBB receptor feedback inhibitor 1
ERBB receptor feedback inhibitor 1 (ERRFI1) is a protein
from Homo sapiens identified by UniProt accession
Q9UJM3, 462 residues long.
MolForge cross-references it against 0 known binders and
158 disease associations.
Target properties
| Protein name | ERBB receptor feedback inhibitor 1 |
| UniProt accession | Q9UJM3 |
| Gene | ERRFI1 |
| Organism | Homo sapiens |
| Length | 462 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (158)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.39
- hair color · score 0.37
- ulcerative colitis · score 0.36
- lean body mass · score 0.34
- body height · score 0.34
- inflammatory bowel disease · score 0.34
- balding measurement · score 0.31
- hair colour measurement · score 0.31
- fat body mass · score 0.31
- Varicose veins · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UJM3-F1 | alphafold | PREDICTED | 56.55 | — |
Amino-acid sequence (462 residues)
MSIAGVAAQE IRVPLKTGFL HNGRAMGNMR KTYWSSRSEF KNNFLNIDPI TMAYSLNSSA QERLIPLGHA SKSAPMNGHC FAENGPSQKS SLPPLLIPPS ENLGPHEEDQ VVCGFKKLTV NGVCASTPPL TPIKNSPSLF PCAPLCERGS RPLPPLPISE ALSLDDTDCE VEFLTSSDTD FLLEDSTLSD FKYDVPGRRS FRGCGQINYA YFDTPAVSAA DLSYVSDQNG GVPDPNPPPP QTHRRLRRSH SGPAGSFNKP AIRISNCCIH RASPNSDEDK PEVPPRVPIP PRPVKPDYRR WSAEVTSSTY SDEDRPPKVP PREPLSPSNS RTPSPKSLPS YLNGVMPPTQ SFAPDPKYVS SKALQRQNSE GSASKVPCIL PIIENGKKVS STHYYLLPER PPYLDKYEKF FREAEETNGG AQIQPLPADC GISSATEKPD SKTKMDLGGH VKRKHLSYVV SP
Explore ERBB receptor feedback inhibitor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets